Objective: Depression occurs more commonly during the menopausal transition in women with vasomotor symptoms (VMS) than in those without, but most women with VMS do not develop depression. It has been hypothesized that VMS are associated with depression because VMS lead to repeated awakenings, which impair daytime well-being. We aimed to determine if objectively measured sleep and perceived sleep quality are worse in depressed women with VMS than in nondepressed women with VMS.
T he risk of depression increases significantly during perimenopause 1<5 and may continue to be elevated in the early postmenopausal years. 2, 6 Most, 1, 5, 7, 8 but not all, 3, 4 studies have found that depression occurs more commonly during the menopausal transition in women who have hot flashes and night sweats, or vasomotor symptoms (VMS), than in those who do not. Even among women with no history of psychiatric illness, women with VMS are at greater risk for developing a first lifetime episode of depression than those without VMS. 5 The basis for the association between VMS and depression is unknown. One hypothesis, termed the Bdomino hypothesis,[ is widely touted as an explanation for the development of depression during the menopausal transition. This hypothesis proposes that VMS result in depression because they awaken women repeatedly throughout the night, which consequently impairs daytime well-being. 9, 10 The domino hypothesis assumes a strong relationship between VMS and sleep disturbance. However, evidence of the association between VMS and sleep is conflicting, with results varying based on whether subjective sleep quality or objective sleep parameters were assessed. Vasomotor symptoms are strongly associated with poor self-reported sleep quality in perimenopausal and postmenopausal women. 11<19 In a large epidemiologic survey of women with severe VMS, 81.3% reported poor sleep quality and 43.8% met the criteria for the clinical disorder of insomnia. 17 The specific type of sleep disturbance reported by women with VMS involves repeated brief awakenings associated with night sweats. 20 However, studies that measure sleep objectively using polysomnography in healthy postmenopausal women 11,20<23 and breast cancer patients 24 with VMS do not consistently find that VMS are associated with awakenings. Whereas some studies have found that women with VMS spend time awake after sleep onset and have more awakenings 20, 22, 23 and/or reduced sleep efficiency 23, 24 than women without VMS, others report no significant differences in objectively measured sleep parameters between women with and without VMS. 11, 21 The basis for the strong association between VMS and depression is unknown. Although a significant proportion of women with VMS also meet the criteria for depression, not all women with VMS become depressed, suggesting that sleep disturbance or other factors may differ between those women with VMS who do and do not become depressed. 8 If the domino hypothesis is correct, variability in the number of nocturnal VMS, the number of awakenings after sleep onset, and/or the amount of time spent awake after sleep onset would be expected to influence the likelihood that depression occurs in this population. It is therefore critical to examine the type of sleep disturbance seen in depressed women with VMS to determine if the type of sleep disturbance they experience differs from that of nondepressed women who also have VMS. The purpose of this study was to delineate the type of sleep disturbance observed in depressed women to address the hypothesis that women with VMS and depression have greater disturbance in objectively measured sleep and in subjectively reported sleep quality than nondepressed controls with VMS.
METHODS

Participants
Participants were enrolled in one of three concurrently conducted clinical trials for treatment of VMS in depressed perimenopausal and postmenopausal women with spontaneous VMS, 1 nondepressed perimenopausal and postmenopausal women with spontaneous VMS, 2 and nondepressed women with breast cancer who had VMS induced by antiestrogen therapies. 3 The two nondepressed groups were treated as one control group because there was no difference between the two groups in subjective sleep quality, time in bed, total sleep time, sleep latency, or number of hot flashes reported or measured objectively. In total, 52 women with depression and VMS and 51 nondepressed women (25 with spontaneous VMS and 26 with VMS induced by antiestrogen therapies) participated in the study.
Participants were recruited from primary care, psychiatry, gynecology, and oncology outpatient clinics and the community. All were women 40 years or older reporting VMS and sleep disturbance associated with VMS who were seeking treatment for VMS. At the time of enrollment, none of them had received treatment with medications that treat VMS, sleep, and depression for at least 2 weeks. Informed consent was obtained from all participants at study entry, and study procedures were approved by the local institutional review board.
In addition to VMS and associated sleep disturbance, depressed and control participants were required to have menstrual cycle irregularities consistent with the Stages of Reproductive Aging Workshop criteria for late menopausal transition (Q1 cycle in the past year but skipped 92 cycles) or postmenopause status (amenorrhea 912 mo). 25 Breast cancer controls were required to have developed VMS from antiestrogen therapy (85% were taking tamoxifen, 15% were taking aromatase inhibitors; median duration of use, 17 mo; range, 2-54 mo) rather than from natural menopause. However, most (77%) breast cancer participants were perimenopausal or postmenopausal. Breast cancer patients had been diagnosed 36 T 24 months before enrollment, and all had completed chemotherapy and radiation therapy 3 months or longer previously.
Except for depression criteria, all other study inclusion criteria were identical for depressed women and nondepressed controls: (1) 14 VMS or more per week for 2 weeks or longer; (2) awakenings that began when VMS developed; (3) 3 or more awakenings associated with VMS per night occurring 3 nights or more per week; (4) no current or recent use of psychiatric medications, sleep medications, or exogenous hormones; and (5) no diagnosis of sleep apnea, periodic limb movement disorder, or narcolepsy. The presence of VMS (Q14 VMS per week) was confirmed prospectively with a 7-day diary.
Sleep symptoms were evaluated to be unrelated to primary sleep disorders using a clinical interview and standard cutoff scores on the Sleep Disorders Questionnaire (SDQ) for sleep apnea, periodic limb movement disorder, and narcolepsy. 26 All participants met research diagnostic criteria for an insomnia syndrome for 1 month or more, with a deleterious impact of sleep disruption on daytime well-being or function. 27 Participants were classified as having depression if they met the diagnostic criteria for one of three depression diagnoses (major depression, minor depression, or dysthymia). The temporal sequence between the onset of VMS and the depression disorder was not specified. A depression diagnosis was confirmed to be present in depressed participants and to be absent in nondepressed controls based on the clinician-rated Structured Clinical Interview for the DSM-IV Axis I Disorders 28 and self-administered Patient Health Questionnaire. 29 The diagnosis of a depressive disorder with the Structured Clinical Interview for Diagnostic and Statistical Manual of Disorders requires that sadness and/or lack of pleasure be present in addition to several neurovegative symptoms of depression (eg, fatigue). Use of this standardized approach to depression categorization restricted the depressed group to those who met the criteria for a depression disorder, rather than also including women who have daytime symptoms resulting from sleep deprivation (eg, fatigue). Women were excluded from participating in this study if they had psychotic symptoms or suicidal ideation or met the criteria for bipolar, psychotic, anxiety, eating, alcohol, or drug abuse disorders.
Procedures
The study involved a 1-week cross-sectional assessment of VMS, sleep disturbance, and mood. VMS and sleep parameters were measured objectively in participants' homes for two consecutive nights during a 7-day period in which a subjective VMS diary and sleep quality assessments were completed. Participants were instructed to maintain routine sleep habits during the study.
Sleep
Objective sleep parameters were assessed using an actigraphic watch (Mini Mitter Co, Inc, Bend, OR), which was worn for two nights in each participant's home, maintaining her natural sleeping environment. Actigraphic sleep assessments identify sleep and wake states based on measurements of motor activity acceleration that have been standardized against polysomnography. 30<35 Actigraphic watches were worn on the wrist of the nondominant hand. Data were collected in 30-second epochs, with an awake state defined when the total activity count exceeded a sensitivity threshold of 80 activity counts during each epoch, a threshold that correlates strongly with wake status as defined by polysomnography. 23 Participants pushed event markers on the watch to indicate when they got into bed and when they got out of bed in the morning to calculate the amount of time that they spent in bed (time in bed). These event markers were used together with the Actiwatch software to calculate objective assessments of total sleep time (amount of actual time spent asleep), sleep efficiency (proportion of time in bed that is filled by sleep), and sleeponset latency (time to fall asleep at beginning of the night). Actigraphy was also used to determine objective measurements of sleep interruption, including wake time after sleep onset (amount of time spent awake after falling asleep at the beginning of the night and waking up in the morning), and the number and average duration of awakenings.
Subjective sleep quality was assessed using the Pittsburgh Sleep Questionnaire Index (PSQI), a widely administered 19item self-rated questionnaire that measures quality of sleep during the past month (range, 0-21; higher score implies worse sleep quality). 36 PSQI scores greater than 5 distinguish poor sleepers from good sleepers. 36 
VMS
Nocturnal VMS frequency was measured using ambulatory sternal skin-conductance monitoring, a validated physiologic measure of VMS. 37, 38 The Biolog ambulatory skin-conductance monitor (UFI, Morro Bay, CA) is a lightweight, portable single-channel device that samples skin conductance at 1 Hz via two Medi-trace sliver/silver chloride electrodes filled with 0.05 M potassium chloride Unibase/ glycol paste that are affixed to the sternum. Conventional VMS criteria of an increase of 2 Kmho or greater within 30 seconds (20-min minimal interflash scoring interval) were applied. 37, 38 The Kmho unit of measurement of skin conductance is the inverse of ohm, a common measure of electrical resistance.
Participants wore the skin-conductance monitor in their own home for two consecutive nights concurrent with the actigraphic monitor to determine the relationship between individual hot flashes and awakenings and to establish a reliable estimate of both VMS and objectively measured sleep parameters 39, 40 while minimizing participant burden. The skin-conductance monitor was programmed to be time synched with the actigraphic watch. Any hot flash recorded between bedtime and wake-up time was defined as an objectively measured nocturnal VMS.
In addition to objective hot flash monitoring, VMS occurring during the day and night were also reported subjectively with the widely used 7-day North Central Cancer Treatment Group diary. 41 Participants reported the number and severity of hot flashes experienced during the daytime at the end of day and the number and severity of hot flashes experienced during the night upon awakening in the morning. Vasomotor symptoms were assessed both objectively and subjectively because the correlation between these assessment methods is limited, with women tending to underreport VMS relative to the number that are measured objectively. 15, 42 Additional assessments
In addition to undergoing a structured psychiatric diagnostic evaluation, all participants completed the Beck Depression Inventory 43 to measure the severity of depressive symptoms among those with versus without a clinical diagnosis of depression. The body density index is a wellvalidated and widely used self-administered 21-item questionnaire that assesses the severity of depressive symptoms during the past 7 days (range, 0-63; higher score implies worse sleep quality) which was used to measure depressive symptoms during the study.
Overall quality of life was also assessed to determine if the presence of depression is associated with a worse sense of well-being, even among women with bothersome VMS and sleep disturbance. Quality of life was assessed with the Quality of Life Inventory, a 16-item, self-administered instrument (range, 0%-100%; lower score implies worse quality of life) that addresses multiple different life domains (health, work, recreation, friendships, love relationships, home, self-esteem, and standard of living), rather than menopause-or health-related symptoms of VMS, sleep, and mood. 44, 45 Height and weight were measured to calculate body mass index (BMI).
Hormone analysis
Serum follicle-stimulating hormone (FSH) levels were measured in the Massachusetts General Hospital Reproductive Endocrine Laboratory using a two-site monoclonal nonisotopic system according to the manufacturer's directions (Axsym; Abbott Laboratories, Abbott Park, IL), as previously described, 46, 47 and expressed in international units per liter as equivalents of the Second International Pituitary Standard 78/549. The interassay coefficients of variation are 5.2%, 4.6%, and 5.5% for quality control sera containing 7.4, 15.6, and 42.0 IU/L, respectively. FSH levels were obtained to support the clinical determination of perimenopause and postmenopause status as the source of VMS and to confirm perimenopause/postmenopause status among women who had undergone a hysterectomy only. FSH levels were not obtained for breast cancer patients because the etiology of VMS was required to be the antiestrogen therapy and not menopause.
Statistical analysis
Differences in objectively measured sleep parameters and perceived sleep quality between depressed participants and controls were examined using Student's t tests for normally distributed data and Wilcoxon nonparametric tests for nonnormal data. For outcomes recorded over two nightsVthat is, objectively measured VMS frequency and sleep parameters (total sleep time, time in bed, sleep efficiency, sleep-onset latency, time awake after sleep onset, number and duration of awakening), an average of the two nights was calculated for each participant and treated as the outcome variable to obtain a more stable estimate for each participant. 39, 40 For sleep outcomes that differed between depressed participants and controls women, multiple linear regression models were built with each sleep outcome of interest as the dependent measure and depression status as the independent variable. Models were then adjusted for hot flash frequency (first objectively and then subjectively measured), and after candidate variables were selected based on content expertise (age, race, BMI, menopause status, and FSH), those demographic factors that differed between depressed and nondepressed participants at P G 0.10 (race, BMI, and menopause status) were included in final models. No interactions were tested.
Adjustments for multiple comparisons were not made because we were testing hypotheses about the association between depression and distinct parameters of sleep disturbance in this population. 48 Statistical analyses were conducted using STATA (STATA Corporation, College Station, TX), and statistical significance was set at > = 0.05.
RESULTS
Characteristics of study participants
Depressed participants (n = 52) met the diagnostic criteria for major depression (69.2%), dysthymia (17.3%), and minor depression (13.5%). Compared with nondepressed women (n = 51), depressed participants had more depression symptoms (median body density index, 18; interquartile range [IQR], 12-23 vs 4; IQR, 1-9; P G 0.001) and worse quality of life (Quality of Life Inventory, 16%; IQR, 3%-49% vs 55%; IQR, 34%-90%; P G 0.001), consistent with the diagnosis of a depression disorder.
The groups did not differ in age and were mainly white, although fewer depressed women were white (P = 0.01). More depressed than nondepressed women were overweight or obese (P = 0.003). Elevated FSH levels confirmed perimenopause/postmenopause status, but more women in the depressed group were perimenopausal, whereas more in the nondepressed group were postmenopausal (P G 0.001).
The frequency of VMS did not differ between depressed and nondepressed participants, regardless of whether they were assessed objectively using the skin-conductance monitor or subjectively using the VMS diary (Table 1) . Depressed women reported experiencing a median of 5.2 VMS during a 24-hour period and a median of 2.4 VMS during the night on a 7-day diary, and objective monitoring detected a median of one hot flash per night. Similarly, nondepressed women reported 7.0 VMS per 24 hours and 2.7 VMS during the night, and objective monitoring detected a median of one hot flash per night. There was no significant difference between the depressed and nondepressed groups in the proportion of VMS that was associated with an awakening, based on a 2-minute interval between the hot flash and awakening used in previous studies. 21 
Comparison of objective and subjective sleep measures between depressed versus nondepressed women with VMS
Objective assessments of selected parameters of sleep were worse in depressed than in nondepressed women (Fig. 1A) . Depressed women with VMS had shorter total sleep time (by 47.7 min; P = 0.008) and longer sleep-onset latency (by 13.8 min; P = 0.03) than nondepressed controls. There was a trend toward statistical significance for a lower sleep efficiency (by 3.2 percentage points; P = 0.09) in women with depression. However, there was no difference between depressed and nondepressed participants in objective measures of sleep interruption (Fig. 1B) ; depressed participants did not spend more time awake after sleep onset than nondepressed controls, nor did they awaken more frequently or spend more time awake with each awakening ( Table 2) . Subjective measures of sleep (Fig. 1C ) revealed that depressed women perceived worse sleep quality than nondepressed women (PSQI, 12.0 T 3.3 vs 8.3 T 3.7, respectively; P G 0.001), with PSQI scores greater than 5 in 96% of depressed participants, compared with 69% in controls (P G 0.001). In addition, depressed participants spent less time in bed than nondepressed women (by 64.8 min; P G 0.001), based on real-time event markers on the actigraphic watch. Using event markers used to record final wake-up time, depressed women indicated waking up an average of 17 minutes earlier than nondepressed women, a difference that was not statistically significantly different (6:25 A.M. T 83 min vs 6:42 A.M. T 76 min, respectively; P = 0.16), sug-gesting that they did not have early-morning awakening. However, there was a significant difference between the bedtime of depressed and nondepressed women, with depressed women getting into bed an average of 36 minutes later than nondepressed women (11:42 P.M. T 105 min vs 11:06 P.M. T 80 min, respectively; P = 0.008).
The difference in objectively measured sleep outcomes and subjective perception of sleep quality remained significant after adjusting for the number of VMS (regardless of whether measured subjectively or objectively). In these bivariate models, depression was associated with a shorter total sleep time (P = 0.01), longer sleep-onset latency (P = 0.04), less time in bed (P = 0.01), and the perception of worse sleep quality (P G 0.001). There was no significant relationship between VMS and any of these sleep outcomes in adjusted models. Further adjustment for demographic factors that differed between depressed and nondepressed women (race, BMI, and menopause status) did not alter the strong association between depression and sleep measures ( Table 2) , with the depressed group continuing to have a shorter total sleep time (P = 0.04), longer sleep-onset latency (P = 0.03), and perception of worse sleep quality (P G 0.001). sleep efficiency or time in bed after adjustment for VMS, race, BMI, and menopause status.
No association was found between depression and either
DISCUSSION
Our findings indicate that there are important differences in objectively measured sleep parameters and perceived sleep quality between depressed and nondepressed perimenopausal and postmenopausal women with VMS and sleep disturbance. Depressed women spent less time in bed and had shorter total sleep time, longer sleep-onset latency, and a trend toward lower sleep efficiency than nondepressed women, but measurements of sleep interruption (wake time after sleep onset, number of awakenings, duration of awakenings) did not differ between depressed and nondepressed participants. Depressed women also reported that they had worse perceived sleep quality than nondepressed women with VMS. The association between depression and worse sleep was seen despite a comparable frequency of nocturnal VMS in the two groups.
Our results do not lend support to the domino hypothesis as an explanation for the development of depression during the menopausal transition because the type of sleep disturbance that differentiated depressed from nondepressed women did not include interruption of sleep that is typically associated with hot flashes. We did not observe an increased frequency of nocturnal VMS, more awakenings, or more time spent awake after sleep onset, which would be predicted by the domino hypothesis to explain that depression develops in perimenopausal and postmenopausal women, because VMS interrupt sleep.
If sleep is involved as an intermediate factor between VMS and depression, other measures of sleep fragmentation or changes in sleep architecture that cannot be detected by actigraphy may be involved. It is also plausible that the relatively low number of hot flashes reported and measured per night in our study population limits our ability to detect the impact of VMS on sleep. However, the number of nocturnal VMS reported is representative of the general population with VMS, 49 a proportion of whom will also experience depression. Our results do not exclude the possibility that VMS may exacerbate the sleep disturbance of depression and/or that factors that cause VMS, such as estrogen withdrawal, may concurrently result in insomnia and depression in susceptible women. Definitive evidence of a causal pathway between VMS, sleep disturbance, and depression requires a more direct mechanistic study and cannot be established with this cross-sectional study design.
Although the depressed participants spent on average 1 hour less time in bed than the nondepressed women, they did not have shorter sleep-onset latency or better sleep efficiency than the nondepressed group, which is the expected compensatory response to sleep deprivation resulting from less time spent in bed among healthy individuals. 50 In contrast, our depressed participants showed the opposite effectVlonger sleep-onset latency and a trend toward lower sleep efficiency, consistent with a significant abnormality of sleep seen in the clinical disorder of insomnia. 27 Thus, the depressed participants had significant insomnia, involving a perception of sleep quality that is disproportionately worse than what is measured objectively.
Our work expands on previous studies that have found that perimenopausal and postmenopausal women with VMS and mild depressive symptoms report perceiving worse sleep quality than those with VMS alone. 15, 51 However, unlike studies that found that objectively measured sleep does not differ between those with and without depressive symptoms in postmenopausal women, 51 we found important differences in objectively measured sleep. Our study results may differ because we included women with clinically relevant depressive disorders, rather than only mild depressive symptoms. By specifically comparing sleep parameters in women with versus without clinical depression, our work drew greater contrast between the two groups of women and provides stronger evidence that mood disturbance is associated with sleep abnormalities among women with VMS.
The clinical disorder of depression can involve difficulty falling asleep, staying asleep, and/or early-morning awakening on objective monitoring and reduced sleep quality on subjective assessments. 52 Indeed, our study found that depressed women with VMS got into bed later and had more problems falling asleep, but not more problems staying asleep or G0.001 j3.8 (1.0) G0.001 NS, not significant. a Regression coefficient (and SE) for the depressed versus the nondepressed group. b Models adjusted for number of vasomotor symptoms, race, body mass index, and menopause status include 68 participants or more. c Perceived sleep quality measured by the Pittsburgh Sleep Questionnaire Index (range, 0-21; higher score implies worse sleep quality). 36 early-morning awakening, than nondepressed women with VMS. Sleep disturbance is both a symptom manifestation of depression 52 and increases the likelihood that depression will develop. 53 Thus, the temporal relationship between sleep disturbance and depression is complex and can be bidirectional, with sleep disturbance either preceding or following the onset of depression. However, because ours is a crosssectional study, we are unable to determine if the depressed participants had worse sleep as a symptom manifestation of their depression, or if these women developed depression as a result of greater sleep disturbance. The relationship between VMS and depression may similarly be bidirectional, with some recent studies suggesting that depression symptoms can, at times, precede, rather than follow, the development of VMS. 54 Future studies that assess the temporal relationship between VMS, sleep, and mood prospectively are needed to determine if there is a causal pathway between these core menopause-related symptoms.
Our results no not provide information about the extent to which VMS disrupts sleep because we did not include a control group without VMS. Several studies that do address the impact of VMS on sleep have reported that women with VMS have reduced sleep efficiency, 23, 24 or more awakenings and time-awake after sleep onset, 20,22<24 whereas still others have found that objectively measured sleep did not differ between those with and without VMS. 11, 21 Our nondepressed control group was divided equally between women with spontaneous VMS and those with VMS induced by antiestrogen therapy. Women with breast cancer had been diagnosed an average of 3 years before study enrollment and were not undergoing chemotherapy or radiation treatment at the time of the study. Although merging this control group introduces some heterogeneity, there was no difference between these subgroups in subjective sleep quality (PSQI), time in bed, total sleep time, sleep latency, or number of hot flashes reported or measured objectively. These findings suggest that VMS induced by antiestrogens are not associated with worse sleep than spontaneous VMS seen in perimenopausal and postmenopausal women.
An important strength of the current study it that we used both subjective and objective assessment methods to measure VMS and sleep parameters. Some studies have measured sleep, but not VMS, objectively, 51 whereas others have measured VMS, but not sleep, objectively. 15 Objective measurements are important to obtain in studies examining the association between depression and other subjectively reported symptoms because depression can influence the reporting of both sleep 52 and VMS. 15 It is notable that both depressed and nondepressed women in our study reported experiencing more VMS at night than were detected objectively. This finding is in contrast to other studies, in which more nocturnal VMS were measured objectively than were reported subjectively in healthy perimenopausal and postmenopausal women 15 and women with breast cancer. 42 However, unlike other studies of nocturnal VMS, 15, 42 our study selected women who reported experiencing sleep disturbance in conjunction with their VMS, which may influence the relationship between the number of VMS that are perceived versus detected during the night. Regardless, associations between depression and sleep disturbance were observed whether nocturnal VMS were measured subjectively or objectively.
Another study strength is the use of objective measures in an ambulatory setting. Because we conducted objective sleep assessments in the participants' natural sleeping environment and instructed them to maintain their usual sleep habits, our assessments are more representative of the participants' true sleep than would be seen in the sleep laboratory setting. This approach to objective sleep monitoring enabled us to detect the reduced time spent in bed in the depressed women, an important parameter of sleep disturbance that has not been previously described and would not have been identified in the laboratory setting in which time in bed is determined by the sleep center.
In addition to its strengths, this study is limited by the inclusion of a sample of opportunity of women enrolled in three separate clinical trials who were evaluated crosssectionally. Although eligibility criteria in the trials were designed in parallel to make comparisons between these groups of women, there were some differences between the groups (ie, race, menopause status, and BMI). However, these characteristics did not influence the strong association between depression and sleep disturbance in adjusted regression models. The cross-sectional design of the study also limits the causal inferences that can be made about the influence of depression on sleep in women with VMS. Another potential limitation intrinsic to actigraphic assessment is that it can score quiet time as being asleep when an individual is awake in bed and not moving. 55 Polysomnographic corroboration is required to definitively establish whether differences in objectively measured sleep that we observed can be explained in part by differences in the amount of quiet time spent in bed between depressed and nondepressed women.
CONCLUSIONS
In summary, the type of sleep disturbance that differentiated depressed women with VMS from nondepressed women with VMS involved getting into bed later, problems falling asleep, and spending less time in bed and less time asleep, rather than greater interruption of sleep that is typically attributed to hot flashes and proposed in the domino hypothesis 9,10 to explain the occurrence of depression during the menopausal transition. Our data suggest that the nature of the sleep disturbance occurring in depressed women with VMS is more complex than previously thought. Clinicians treating women with VMS should be attentive to the type of sleep disturbance reported. Although perimenopausal and postmenopausal women with VMS are more likely to report worse problems with reduced sleep quality and repeated awakening from sleep than those without VMS, 20 women who report spending less time in bed, less time asleep, and/or problems falling asleep at the beginning of the night should be evaluated for concurrent depression. Our results inform clinical care by emphasizing the importance of focusing treatment on symptoms of sleep disturbance, rather than VMS, concurrent with therapies aimed at managing depression in symptomatic perimenopausal and postmenopausal women.
